Norethandrolone

Summary

Norethandrolone (CHEMBL1697845) is a phase-3 clinical-stage small molecule (ATC A14AA09); indicated across 1 condition including acute myeloid leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A14AA09
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 302.5 Da · C20H30O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1697845
Name	Norethandrolone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5858
ATC	A14AA09
Molecular formula	C20H30O2
Molecular weight	302.5
InChIKey	ZDHCJEIGTNNEMY-XGXHKTLJSA-N

SMILES: CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)O

IUPAC name: (8R,9S,10R,13S,14S,17S)-17-ethyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one

Also known as: Nilevar, Noretandrolona, Norethandrolone, NSC-70581, Pronabol, Solevar, NORETHANDROLONE

Patent coverage: 341 distinct patent families (1,214 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00700544	PHASE3	COMPLETED	Treatment Outcome in Elderly Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).